Alcohol and Longevity: What the Global Burden of Disease Study Found

A 2018 analysis covering one hundred ninety-five countries and territories, published in The Lancet, concluded that the safest level of alcohol consumption is none — overturning decades of messaging around the cardiovascular benefits of moderate drinking. The evidence behind that conclusion, and the reasoning that led to it, is more nuanced than either its critics or its supporters typically acknowledge. The Global Burden of Disease Study 2016 alcohol analysis, published in The Lancet in 2018, pooled data from eighty-three prospective studies covering one hundred ninety-five countries to estimate the relationship between alcohol use and twenty-three health outcomes — ranging from cardiovascular disease and multiple cancers to liver disease, road injuries, and tuberculosis. The headline conclusion — that the safest level of drinking is none — was widely reported and widely contested. The reasoning behind it is specific: when all twenty-three outcomes are combined into a net health burden estima --- Paper cited: Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Authors: GBD 2016 Alcohol Collaborators Journal: The Lancet Year: 2018 DOI: 10.1016/S0140-6736(18)31310-2 --- Subscribe for one peer-reviewed paper made practical, every Tuesday and Friday. Free guide: How to Read Your Biomarker Panel at 55+ - {{LEAD_MAGNET_URL}} --- EDUCATIONAL CONTENT - NOT MEDICAL ADVICE This video is for general educational and informational purposes only. It summarizes peer-reviewed research. It does NOT constitute: - Medical advice, diagnosis, or treatment - Recommendations to start, stop, or change any medication - Dosing instructions for supplements or interventions - A substitute for consultation with a licensed physician Before applying anything discussed: - Talk to your physician, especially if you take prescription medications (statins, metformin, blood thinners, antihypertensives, GLP-1 agonists, etc.) - Discuss interactions, contraindications, and your individual risk profile - Get baseline biomarkers before changing your regimen if relevant Specific cautions: - Intermittent fasting: not appropriate for people with diabetes (especially Type 1), history of eating disorders, pregnancy, or underweight status without medical supervision. - Strength/Zone-2 training: medical clearance recommended for cardiovascular or joint conditions before initiating new training loads. - Supplements: third-party tested products preferred; verify drug interactions. AFFILIATE DISCLOSURE (FTC compliant): Some links in the description may be affiliate links. We may earn a commission at no additional cost to you. We only feature products and tools relevant to the research discussed. AI-ASSISTED PRODUCTION: Voice narration is generated via Edge TTS (Microsoft Neural Voice). Research, scriptwriting, and review are conducted by a human editor before publication. Reviewed: 2026-09-02